IGSF8 and acute myeloid leukemia: In contrast, in hematological malignancies such as acute myeloid leukemia, IGSF8 sustains leukemic stemness by stabilizing β-catenin, preventing its degradation and enhancing Wnt pathway activation, which in turn promotes therapy resistance and disease progression (12).